| Literature DB >> 26622607 |
Sachi Morita1, Mariko Hiramatsu2, Mihoko Sugishita1, Bishal Gyawali1, Takashi Shibata1, Tomoya Shimokata1, Hiroshi Urakawa1, Ayako Mitsuma1, Suzuko Moritani3, Toshinobu Kubota4, Shu Ichihara3, Yuichi Ando1.
Abstract
Granular cell tumors are uncommon, usually benign tumors of Schwann cell origin. The malignant variant is extremely rare, representing <2% of all granular cell tumors. Therefore, standard systemic chemotherapy for this disease does not exist. The present study reports the case of a 40-year-old female with a malignant granular cell tumor that originally arose in the right orbit and subsequently relapsed. The patient was started on pazopanib monotherapy following treatment with two investigational drugs, a smoothened inhibitor and then a phosphatidylinositol 3-kinase inhibitor, as part of a clinical trial. Although additional radiotherapy for local control was necessary, the lung metastases remained stable during the pazopanib monotherapy, which lasted for 7 months, following which a clinically stable disease state was determined. This case suggests that pazopanib can be a treatment option for the stabilization of disease progression in metastatic malignant granular cell tumor.Entities:
Keywords: malignant granular cell tumor; orbit; pazopanib
Year: 2015 PMID: 26622607 PMCID: PMC4509081 DOI: 10.3892/ol.2015.3263
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967